肝癌切除术后辅助性经肝动脉化疗栓塞术对患者生存的影响及预后相关因素分析

邢志祥; 沈世强; 秦峰; 杨强; 叶子

doi:10.3969/j.issn.1001-5256.2017.12.015

肝癌切除术后辅助性经肝动脉化疗栓塞术对患者生存的影响及预后相关因素分析

DOI: 10.3969/j.issn.1001-5256.2017.12.015

武汉大学人民医院肝胆腔镜外科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 372
- HTML全文浏览量: 49
- PDF下载量: 86
- 被引次数: 0
出版历程
- 收稿日期: 2017-06-05
- 出版日期: 2017-12-20

Effect of postoperative adjuvant transarterial chemoembolization on postoperative survival of patients with liver cancer and related influencing factors for prognosis

Department of Hepatobiliary & Laparoscopic Surgery, Renmin Hospital of Wuhan University

摘要

摘要: 目的探讨肝切除术后辅助性经肝动脉化疗栓塞术（TACE）对肝细胞癌（HCC）患者生存的影响,并分析影响其预后的相关因素。方法回顾性分析2007年1月-2012年12月武汉大学人民医院收治的215例HCC患者的临床资料。根据肝切除术后是否联合TACE治疗分为单纯组（95例）及联合组（120例）。单纯组采用单纯肝切除术治疗,联合组先行肝切除术,术后1个月给予TACE治疗。记录2组患者一般情况、治疗情况及相关临床指标,比较2组患者术后1、3、5年生存率及无瘤生存率。计量资料组间比较采用独立样本t检验,计数资料组间比较使用χ2检验。组间生存比较采用Kaplan-Meier生存分析,采用单因素分析及Cox多因素回归分析肝切除术后预后的影响因素。结果联合组术后1、3、5年生存率分别为96.5%、67.0%、51.0%,中位生存期为51个月;单纯组分别为84.0%、49.5%、36.5%,中位生存时间为39个月,2组生存率差异有统计学意义（χ2=5.540,P=0.018）。联合组术后1、3、5年无瘤生存率均分别为91.7%、62.5%、37.5%,单纯组分别为84.0%、42.1%、26.3%,差异...
- 癌,肝细胞 /
- 化学栓塞,治疗性 /
- 肝切除术 /
- 预后 /
- 危险因素
Abstract: Objective To investigate the effect of postoperative adjuvant transarterial chemoembolization ( TACE) on the survival of patients with hepatocellular carcinoma ( HCC) , as well as influencing factors for prognosis. Methods A retrospective analysis was performed for the clinical data of 215 HCC patients who were admitted to Renmin Hospital of Wuhan University from January 2007 to December 2012. According to whether TACE was given after hepatectomy, these patients were divided into single group with 95 patients and combination group with120 patients. A comparative analysis was performed for the two groups. The patients in the single group were given hepatectomy alone, and those in the combination group were given hepatectomy followed by TACE at one month after surgery. General status, treatment condition, and related clinical indices were recorded for both groups, and the two groups were compared in terms of the 1-, 3-, and 5-year survival rates and disease-free survival rates after surgery. The independent samples t-test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. The Kaplan-Meier method was used for comparison of survival rates between groups, and univariate analysis and Cox multivariate regression analysis were used to investigate the influencing factors for prognosis after hepatectomy. Results In the combination group, the 1-, 3-, and 5-year survival rates were 96. 5%, 67. 0%, and 51. 0%, respectively, with a median survival time of 51 months; in the single group, the 1-, 3-, and 5-year survival rates were 84. 0%, 49. 5%, and 36. 5%, respectively, with a median survival time of 39 months; there was a significant difference in survival rates between the two groups ( χ2= 5. 540, P = 0. 018) . The 1-, 3-, and 5-year disease-free survival rates were 91. 7%, 62. 5%, and 37. 5%, respectively, in the combination group and 84. 0%, 42. 1%, and 26. 3%, respectively, in the single group, and there was a significant difference between the two groups ( χ2= 4. 942, P = 0. 027) . Preoperative alpha-fetoprotein > 400 μg/L, TNM stage III, multiple tumors, tumor diameter > 5 cm, positive HBs Ag, and vascular invasion were independent prognostic factors in patients after hepatectomy, while TACE was a protective factor for long-term survival of these patients. Conclusion Adjuvant TACE after hepatectomy can significantly improve the survival rate and disease-free survival rate of HCC patients and has great significance in improving surgical outcome.
- carcinoma, hepatocellular /
- chemoembolization, therapeutic /
- hepatectomy /
- prognosis /
- risk factors

HTML全文

参考文献(18)

[1]TATEISHI R, SHIINA S, AKAHANE M, et al.Frequency, risk factors and survival associated with an intrasubsegmental recurrence after radiofrequency ablation for hepatocellular carcinoma[J].PLo SOne, 2013, 8 (4) :e59040.

[2]HUANG WK, YANG SF, YOU LN, et al.Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLCstage B hepatocellular carcinoma refractory to TACE[J].Contemp Oncol (Pozn) , 2016, 20 (6) :468-474.

[3]HINRICH JB, HASDEMIR DB, NORDLOHNE M, et al.Health-related quality of life in patients with hepatocellular carcinoma treated with initial transarterial chemoembolization[J].Cardiovasc Intertvent Radiol, 2017, 40 (10) :1559-1566.

[4]SHEN YN, LU JH, YANG T.Recent advances in molecular mechanisms of hepatocellular carcinoma[J].J Hepatobiliary Surg, 2014, 22 (2) :157-160. (in Chinese) 沈艺南, 卢军华, 杨田.肝细胞癌相关分子机制研究新进展[J].肝胆外科杂志, 2014, 22 (2) :157-160.

[5]LIU YY, LIU XX.International controversy in partial hepatectomy for patients in stage B or C of Barcelona Clinic Liver Cancer[J].Chin J Dig Surg, 2015, 14 (8) :609-611. (in Chinese) 刘允怡, 刘晓欣.巴塞罗那临床肝癌B期和C期患者施行部分肝切除术治疗的国际争议[J].中华消化外科杂志, 2015, 14 (8) :609-611.

[6]LI SY, WU S, CHEN TS, et al.Effect of portal venous perfusion cinobufacini injection combined with TACE in patients with intermediate hepatocellular carcinoma[J].Chin J Med Offic, 2017, 45 (9) :884-886. (in Chinese) 李淑英, 吴申, 陈挺松, 等.经导管肝动脉栓塞化疗联合华蟾素门静脉灌注治疗中期原发性肝癌疗效研究[J].临床军医杂志, 2017, 45 (9) :884-886.

[7]MA M, NIU TT, SHAO L, et al.Hepatic transcatheter arterial chemoembolization combined with stereotactic radiation therapy of primary liver cancer[J].Trauma Crit Med, 2017, 5 (1) :32-35. (in Chinese) 马明, 牛婷婷, 邵亮, 等.肝动脉化疗栓塞术联合立体定向放疗治疗较大原发性肝癌临床研究[J].创伤与急危重病医学, 2017, 5 (1) :32-35.

[8]ZHONG C, GUO RP, LI JQ, et al.A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma[J].J Cancer Res Clin Oncol, 2009, 135 (10) :1437-1445.

[9]MATHURIN P, RAYNARD B, DHARANCY S, et al.Meta-analysis:evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma[J].Aliment Pharmacol Ther, 2003, 17 (10) :1247-1261.

[10]SUN JJ, WANG K, ZHANG CZ, et al.Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion[J].Ann Surg Oncol, 2016, 23 (4) :1344-1351.

[11]YU MH, KIM JH, YOON JH, et al.Small hepatocellular carcinoma:diagnostic performance and imaging features at gadoxetic acidenhanced MR imaging[J].Radiology, 2014, 271 (3) :748-760.

[12]REN ZG, LIN ZY, XIA JL, et al.Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor:a retrospective control study[J].World J Gastroenterol, 2004, 10 (19) :2791-2794.

[13]LI C, WEN T, YAN L, et al.Liver resection versus liver resection plus TACE for patients with hepatocellular carcinoma beyond Milan criteria[J].J Surg Res, 2017, 209:8-16.

[14]TONG Y, LI Z, LIANG Y, et al.Postoperative adjuvant TACE for patients of hepatocellular carcinoma in AJCC stage I:friend or foe?A propensity score analysis[J].Oncotarget, 2017, 8 (16) :26671-26678.

[15]DONG ZR, ZHANG PF, WANG CH, et al.Postoperative adjuvant transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond the Milan criteria:a retrospective analysis[J].Am J Cancer Res, 2015, 5 (1) :450-457.

[16]CHEN J L, LIN X J, ZHOU Q, et al.Association of HBV DNAreplication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection[J].Chin J Cancer, 2016, 35:28.

[17]HUANG G, YANG Y, SHEN F, et al.Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load[J].Ann Surg Oncol, 2013, 20 (5) :1482-1490.

[18]HUANG G, LAU WY, WANG ZG, et al.Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma:a randomized controlled trial[J].Ann Surg, 2015, 261 (1) :56-66.

施引文献

资源附件(0)

访问统计